Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Armodafinil | Coluracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 75-150 mg once daily (for educational context only — prescription medication in most jurisdictions) | 20-80 mg/day divided into 2-3 doses |
| Timing | Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours. | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. |
| Cycle Duration | Same as modafinil; not typically cycled in clinical use. | Cycles of 4-8 weeks on, 2-4 weeks off |
| Evidence Level | strong_human | animal_plus_anecdotal |
The isolated R-enantiomer of racemic modafinil, sharing the same primary mechanism — selective inhibition of the dopamine transporter (DAT) — but with distinct pharmacokinetics. The R-enantiomer has a terminal half-life of ~15 hours vs. ~4-5 hours for the S-enantiomer, resulting in 33-40% higher plasma AUC compared to equimolar racemic modafinil. This translates to more sustained wakefulness-promoting activity throughout the day. Same downstream activation of orexinergic, histaminergic, and noradrenergic pathways as modafinil.
75-150 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours.
Same as modafinil; not typically cycled in clinical use.
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →